Blood polypeptide group COVID-19 biomarker

A biological marker, blood technology, applied in biological testing, biological material analysis, material testing products, etc., can solve problems such as lack of clinical research

Pending Publication Date: 2021-12-21
GUANGZHOU EIGHTH PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, there is currently no direct evidence to prove that the new coronavirus induces type 1 diabetes, especially COVID-19 causes insulin resistance, leading to hyperglycemia
However, there is a lack of clinical studies and related mechanistic studies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Blood polypeptide group COVID-19 biomarker
  • Blood polypeptide group COVID-19 biomarker
  • Blood polypeptide group COVID-19 biomarker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] A blood peptide group new crown biomarker, including myeloperoxidase (Myeloperoxidase, MPO), Apelin, myostatin (GDF8).

experiment example 1

[0021] Collect 10 cases of healthy people, 34 cases of infection period patients without basic metabolic diseases, and 34 cases of convalescence patients without basic metabolic diseases. Serum was detected by Luminex kit to detect insulin content and calculate HOMA-IR value; the results are as follows: figure 1 As shown, HOMA-IR in the serum of patients with new crown virus remained abnormal during the recovery period and could not return to normal state, which proved that the new coronavirus infection caused abnormal metabolism of the body. The results show that the new coronavirus causes insulin resistance in the patient's body. Figure A shows HOMA-IR. Compared with the healthy control group, the HOMA-IR value increases during the infection period, and remains at a high level during the recovery period, unable to return to a normal state. *p<0.05.

experiment example 2

[0023] Collect 10 healthy people, 29 non-severe infectious patients without basic metabolic diseases, 29 non-severe convalescent patients without basic metabolic diseases, 5 severe infectious patients without basic metabolic diseases, and 5 severe convalescent patients without basic metabolic diseases Serum from patients, the contents of MPO, Apelin and GDF8 were detected with Luminex kits. MPO( figure 2 ), Apelin ( image 3 ) and GDF8 ( Figure 4 ) was significantly increased or decreased in both non-severe and severe infection periods, and could not return to normal levels in both non-severe and severe recovery periods. The results showed that the MPO content of patients infected with the new crown was still elevated during the recovery period, while Apelin and GDF8 were still maintained at low levels and could not return to normal. *p<0.05; **p<0.01.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of biomarkers, in particular to a blood polypeptide group COVID-19 biomarker. Theblood polypeptide group COVID-19 biomarker comprises myeloperoxidase (MPO), Apelin and myogenesis inhibition protein (GDF8). The MPO, the Apelin and the GDF8 are all simple and noninvasive blood polypeptide group biomarkers, and the new insulin resistance of a Blood polypeptide group COVID-19 biomarker patient can be rapidly and effectively detected by utilizing the blood polypeptide group biomarkers, so that prevention and symptomatic treatment can be carried out on a COVID-19 patient.

Description

technical field [0001] The invention relates to the technical field of biomarkers, in particular to a blood polypeptide group novel coronavirus biomarker. Background technique [0002] Many COVID-19 patients with metabolic diseases such as diabetes, obesity, hypertension and cardiovascular disease have a very poor prognosis. According to literature reports, the mortality rate of COVID-19 patients with diabetes and hypertension is very high, and the mortality rate of patients with cardiovascular disease is as high as 10.5%. Furthermore, glycemic control worsened in COVID-19 patients with type 2 diabetes, requiring high doses of insulin. Therefore, metabolic complications such as cardiovascular disease may worsen the condition and clinical outcome of COVID-19. In COVID-19 patients, metabolic dysregulation without underlying metabolic-related disease persists until the recovery period. Therefore, a potential association between COVID-19 and metabolism can be inferred. SARS-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2333/908G01N2333/5757G01N2333/475G01N2800/042
Inventor 何溪朱媛媛雷春亮李芳陈思凡李梓伦陈新文刘陈枢彭梅秀彭江云
Owner GUANGZHOU EIGHTH PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap